CERo Therapeutics Holdings

CERO · NASDAQ

$0.0052−$0.0009 (−14.75%)TodayMarket closed · Oct 20, 3:21 PM ET

Prev close $0.0061

CERO analyst rating

HoldConsensus of 2 analysts over the last 12 months. 0% rate it a buy.

Strong buy0
Buy0
Hold2
Underperform0
Sell0

12-month price target · 3 analysts

Average $30.60 (+588361.5% upside)

Low: $30.30
Now: $0.0052
High: $31.50

Upgrades and downgrades

The latest rating actions, newest first

CERO analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
D. Boral Capital	Nov 18, 2025	Downgrade	Buy → Hold	—	29%
Maxim Group	Nov 3, 2025	Downgrade	Buy → Hold	—	27%
D. Boral Capital	Oct 30, 2025	Maintains	Buy	$30.00	29%
D. Boral Capital	Oct 22, 2025	Maintains	Buy	$30.00	29%

The case for and against

Updated Apr 17, 2026

Bull case

CERo Therapeutics Holdings Inc. demonstrates a positive outlook through its innovative CER-T platform, which uniquely integrates innate and adaptive immune functions, positioning the company favorably within the cancer immunotherapy landscape. The reduction in general and administrative expenses by $0.7 million, alongside ongoing advancements and clinical dosing of the CER-1236 product, indicates effective cost management and a commitment to bolstering research and development efforts. Despite experiencing a net loss primarily due to increased R&D expenses, the ongoing clinical milestones related to safety and activity in AML patients remain significant drivers of investor interest.

Bear case

CERo Therapeutics Holdings Inc. has encountered significant financial challenges that negatively impact its stock outlook. The company's move to over-the-counter (OTC) trading restricts institutional participation, reduces liquidity, and increases capital costs, all of which are problematic for an entity that relies heavily on external financing. Furthermore, ongoing difficulties with its capital structure, highlighted by a substantial increase in net loss attributable to common shareholders and concerns over timely funding due to a down-round event, intensify the risks surrounding its near-term financial sustainability.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.